Literature DB >> 21764477

Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer.

Naohiro Kobayashi1, Shingo Usui, Shinji Kikuchi, Yukinobu Goto, Mitsuaki Sakai, Masataka Onizuka, Yukio Sato.   

Abstract

A number of prognostic factors have been reported in non-small cell lung cancer (NSCLC). Although lymph node metastasis is the most poorly predictive value in completely resected NSCLC, a significant number of patients have a fatal recurrence even in node-negative curative NSCLC. Recently inflammatory response has been shown as a predictive value in NSCLC. Neutrophils and lymphocytes play an important role in cancer immune response. In this study, we retrospectively examined the impact of preoperative peripheral neutrophil and lymphocyte counts on survival, and investigated the relationships of these factors to clinicopathological factors in node-negative NSCLC. A total 237 patients were evaluated. When the cut-off value of neutrophil count was 4500 mm(-3) with a maximum log-rank statistical value, overall 5-year survival rates were 79.7% for the low-neutrophil-count group and 69.5% for the high-neutrophil-count group (P=0.04). When the cut-off value of lymphocyte count was 1900 mm(-3) with a maximum log-rank statistical value, overall survival rates were 67.9% for the low-lymphocyte group and 87.7% for the high-lymphocyte group (P<0.001). High-neutrophil-counts were associated with tumor size (P=0.002) and pleural invasion (P<0.001). Low-lymphocyte-counts were correlated with vascular invasion (P=0.018) and recurrence of NSCLC (P=0.01). Multivariate analysis showed that the lymphocyte count was an independent prognostic factor (hazard ratio: 3.842; 95% confidence interval: 1.827-8.078; P<0.001), but the neutrophil count was not (P=0.185). We conclude that a peripheral lymphocyte count, which is associated with vascular invasion, is an independent prognostic factor in node-negative NCSLC.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21764477     DOI: 10.1016/j.lungcan.2011.06.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  49 in total

1.  Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.

Authors:  Yue-Can Zeng; Feng Chi; Rui Xing; Ming Xue; Li-Na Wu; Mei-Yue Tang; Rong Wu
Journal:  Jpn J Clin Oncol       Date:  2015-11-25       Impact factor: 3.019

2.  Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.

Authors:  Hiroshi Kobayashi; Tomotake Okuma; Hiroyuki Oka; Toshihide Hirai; Takahiro Ohki; Masachika Ikegami; Ryoko Sawada; Yusuke Shinoda; Toru Akiyama; Kenji Sato; Satoshi Abe; Hirotaka Kawano; Takahiro Goto; Sakae Tanaka
Journal:  Int J Clin Oncol       Date:  2017-10-31       Impact factor: 3.402

3.  Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy.

Authors:  O Kyu Noh; Seung Yeop Oh; Young Bae Kim; Kwang Wook Suh
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

4.  Preoperative controlling nutritional status (CONUT) is useful to estimate the prognosis after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Kazuto Harada; Yoshifumi Baba; Keisuke Kosumi; Masaaki Iwatsuki; Koichi Kinoshita; Kenichi Nakamura; Yasuo Sakamoto; Yuji Miyamoto; Ryuichi Karashima; Kosuke Mima; Hiroshi Sawayama; Mayuko Ohuchi; Akira Chikamoto; Yu Imamura; Masayuki Watanabe; Hideo Baba
Journal:  Langenbecks Arch Surg       Date:  2017-01-30       Impact factor: 3.445

5.  Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer.

Authors:  Jian Zhang; Shao-Hong Huang; Hui Li; Yun Li; Xiu-Ling Chen; Wei-Qing Zhang; Hui-Guo Chen; Li-Jia Gu
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

6.  Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer.

Authors:  Yuan Gao; Wen-Jie Wang; Qiaoming Zhi; Meng Shen; Min Jiang; Xiaojie Bian; Fei-Ran Gong; Chong Zhou; Lian Lian; Meng-Yao Wu; Jun Feng; Min Tao; Wei Li
Journal:  Oncotarget       Date:  2017-09-27

7.  Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.

Authors:  Kai Wei; Meng Wang; Wei Zhang; Han Mu; Tian-Qiang Song
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

8.  Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.

Authors:  Dong Xie; Mark S Allen; Randolph Marks; Gening Jiang; Zhifu Sun; Frances Nichols; Mingrui Zhang; Chang Chen; Marie-Christine Aubry; Aminah Jatoi; Yolanda I Garces; Aaron Mansfield; Dennis Wigle; Julian Molina; Claude Deschamps; Ping Yang
Journal:  Eur J Cardiothorac Surg       Date:  2018-06-01       Impact factor: 4.191

9.  Usefulness of the neutrophil-to-lymphocyte ratio in predicting lymph node metastasis in patients with non-small cell lung cancer.

Authors:  Chongbiao Huang; Jie Yue; Zengxun Li; Na Li; Jinkun Zhao; Daliang Qi
Journal:  Tumour Biol       Date:  2015-04-29

10.  Prognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapy.

Authors:  Huarong Tang; Honglian Ma; Fang Peng; Yong Bao; Xiao Hu; Jin Wang; Yujin Xu; Ming Chen
Journal:  Mol Clin Oncol       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.